Albireo Pharma Inc Kurs / Umsatz
Was ist das Kurs / Umsatz von Albireo Pharma Inc?
Kurs / Umsatz von Albireo Pharma Inc ist 8.58
Was ist die Definition von Kurs / Umsatz?
Das Kurs-Umsatz-Verhältnis ist der Aktienkurs eines Unternehmens im Vergleich zu seinen Einnahmen.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Kurs / Umsatz von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit kurs / umsatz ähnlich Albireo Pharma Inc
- Indian Overseas Bank hat Kurs / Umsatz von 8.57
- Mirriad Advertising plc hat Kurs / Umsatz von 8.57
- LXP Industrial Trust hat Kurs / Umsatz von 8.57
- Alkyl Amines Chemicals hat Kurs / Umsatz von 8.57
- TradeGo FinTech hat Kurs / Umsatz von 8.58
- Sprott hat Kurs / Umsatz von 8.58
- Albireo Pharma Inc hat Kurs / Umsatz von 8.58
- Beijing PIESAT Information Technology Co hat Kurs / Umsatz von 8.58
- Mirvac Stapled Securities hat Kurs / Umsatz von 8.58
- CG Power and Industrial Solutions hat Kurs / Umsatz von 8.58
- Nuveen Preferred & Income Opportunities Fund hat Kurs / Umsatz von 8.58
- Zoetis Cl.A Dl ,01 hat Kurs / Umsatz von 8.58
- Mid-America Apartment Communities hat Kurs / Umsatz von 8.58